{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T21:49:14Z","timestamp":1769550554458,"version":"3.49.0"},"reference-count":27,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2018,10,31]]},"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:p>Imatinib is a specific tyrosine kinase inhibitor which has been approved for the treatment of Philadelphia chromosome-positive chronic myeloid leukaemia and c-KIT (CD117)-positive gastrointestinal stromal tumours. It has been associated with hepatotoxicity ranging from abnormal liver function tests to acute liver failure along with chronic hepatitis B reactivation. We report the case of a patient who was started on adjuvant treatment with imatinib following resection of a primary gastrointestinal stromal cell tumour of jejunum and developed severe hepatotoxicity. There was no history of risk factors for liver disease, and a search for the underlying causes of hepatotoxicity was unremarkable. Imatinib was stopped and she was treated with steroids which resulted in dramatic improvement of liver function tests. Liver biopsy in this case was not performed because liver function tests improved following discontinuation of imatinib and treatment with steroids. Repeat imaging did not reveal any evidence of tumour recurrence.<\/jats:p>","DOI":"10.1136\/bcr-2018-226740","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T17:19:47Z","timestamp":1545153587000},"page":"e226740","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Imatinib and liver toxicity"],"prefix":"10.1136","volume":"11","author":[{"given":"Mohammad Inamul","family":"Haq","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Nixon","sequence":"additional","affiliation":[{"name":"Beatson West of Scotland Cancer Centre, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian J","family":"Stanley","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,12,7]]},"reference":[{"key":"2025082712051870000_11.1.e226740.1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","article-title":"Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors","volume":"295","author":"Buchdunger","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"2025082712051870000_11.1.e226740.2","first-page":"925","article-title":"Ott KA and Zigler AJ Inhibition of c-kit receptor tyrosine kinase activity by STI 571","volume":"96","author":"Heinrich","year":"2000","journal-title":"a selective tyrosine kinase inhibitor Blood"},{"key":"2025082712051870000_11.1.e226740.3","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603797"},{"key":"2025082712051870000_11.1.e226740.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60500-6"},{"key":"2025082712051870000_11.1.e226740.5","unstructured":"National institute for Clinical Excellence (NICE) Guidance on the use of imatinib for chronic myeloid leukaemia and for the adjuvant treatment of gastrointestinal stromal tumours Technology appraisal guidance TA70 (2003), TA196, 2010."},{"key":"2025082712051870000_11.1.e226740.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.02.014"},{"key":"2025082712051870000_11.1.e226740.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.4452"},{"key":"2025082712051870000_11.1.e226740.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"2025082712051870000_11.1.e226740.9","doi-asserted-by":"crossref","first-page":"6608","DOI":"10.3748\/wjg.v13.i48.6608","article-title":"Imatinib-induced fatal acute liver failure","volume":"13","author":"Ridruejo","year":"2007","journal-title":"World J Gastroenterol"},{"key":"2025082712051870000_11.1.e226740.10","unstructured":"Imatinib. 2018 https:\/\/livertox.nih.gov\/Imatinib.htm (Accessed 1 Jul 2018)."},{"key":"2025082712051870000_11.1.e226740.11","article-title":"A Case of Imatinib-Induced Hepatitis","volume":"9","author":"Bhatty","year":"2017","journal-title":"Cureus"},{"key":"2025082712051870000_11.1.e226740.12","first-page":"3629","article-title":"Hepatitis B viral reactivation secondary to imatinib treatment in a patient with gastrointestinal stromal tumor","volume":"34","author":"Walker","year":"2014","journal-title":"Anticancer Res"},{"key":"2025082712051870000_11.1.e226740.13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.143"},{"issue":"Suppl 1","key":"2025082712051870000_11.1.e226740.14","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0959-8049(09)70047-4","article-title":"Gastrointestinal toxicities of novel agents in cancer therapy","volume":"45 Suppl 1","author":"Asnacios","year":"2009","journal-title":"Eur J Cancer"},{"key":"2025082712051870000_11.1.e226740.15","doi-asserted-by":"crossref","unstructured":"Tong WG , Kantarjian H , O\u2019Brien S , et al . Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukaemia with pre-existing liver and\/or renal dysfunction Cancer. 2010;116:3152\u20139.","DOI":"10.1002\/cncr.25071"},{"key":"2025082712051870000_11.1.e226740.16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.0304"},{"key":"2025082712051870000_11.1.e226740.17","unstructured":"Novartis Pharmaceuticals Corporation Package literature for Glivec. www.glivec.com (Accessed 1 Jul 2018)."},{"key":"2025082712051870000_11.1.e226740.18","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s12032-009-9284-y","article-title":"Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors","volume":"27","author":"Tonyali","year":"2010","journal-title":"Med Oncol"},{"key":"2025082712051870000_11.1.e226740.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2010.04.008"},{"key":"2025082712051870000_11.1.e226740.20","doi-asserted-by":"crossref","unstructured":"Ferrero D , Pogliani EM , Rege-Cambrin G , et al . Complete Reversion of Imatinib-Induced Hepatotoxicity in Chronic Myeloid Leukaemia Patients by Low- Intermediate Dose Corticosteroid Blood (ASH Annual Meeting Abstracts). 2005;106:4856.","DOI":"10.1182\/blood.V106.11.4856.4856"},{"key":"2025082712051870000_11.1.e226740.21","doi-asserted-by":"publisher","DOI":"10.1592\/phco.28.8.1066"},{"key":"2025082712051870000_11.1.e226740.22","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M715"},{"key":"2025082712051870000_11.1.e226740.23","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/COC.0b013e31802b4ef7","article-title":"An acute hepatitis resembling autoimmune hepatitis occurring during imatinib therapy in a gastrointestinal stromal tumor patient","volume":"32","author":"Aliberti","year":"2009","journal-title":"Am J Clin Oncol"},{"key":"2025082712051870000_11.1.e226740.24","doi-asserted-by":"crossref","unstructured":"Ohnishi K , Sakai F , Kudoh S , et al . Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesilate - Letters to the Editor Leukaemia. 2006;20:1162\u20134.","DOI":"10.1038\/sj.leu.2404207"},{"key":"2025082712051870000_11.1.e226740.25","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1097\/MJT.0b013e31826fc5d1","article-title":"Early onset imatinib mesylate-induced hepatotoxicity in a patient with gastrointestinal stromal tumors","volume":"21","author":"Yachoui","year":"2014","journal-title":"Am J Ther"},{"key":"2025082712051870000_11.1.e226740.26","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/1471-2407-12-186","article-title":"Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST)","volume":"12","author":"Seidel","year":"2012","journal-title":"BMC Cancer"},{"key":"2025082712051870000_11.1.e226740.27","doi-asserted-by":"publisher","DOI":"10.1097\/01.meg.0000216941.42306.0e"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bcr-2018-226740","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-226740","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T19:05:24Z","timestamp":1756321524000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-226740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12,7]]},"published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1136\/bcr-2018-226740"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-226740","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}